EGFR Activating Mutation, NSCLC, Recurrent, NSCLC Stage IIIB, NSCLC Stage IV
Conditions
Brief summary
This is a non-interventional, multi-center, ambispective cohort study in real world to describe the effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.
Detailed description
This is a multi-center observational study with both retrospective and prospective data collections to describe the effectiveness and safety of sequential dacomitinib and 3rd generation EGFR-TKI used in patients with EGFR mutation-positive NSCLC with T790M-aquired resistance in a clinical practice setting. The study will include patients who were or will be diagnosed as advanced NSCLC with EGFR mutation positive and received dacomitinib as first-line treatment followed by second-line 3rd generation EGFR-TKI treatment in multiple tertiary care hospitals after Sep 1st, 2019. Patients' clinical information prior to the study initiation in each hospital will be collected retrospectively through chart review. After the study initiation, new patient enrollment will last till Dec 2022. Patients' clinical care after the study initiation will be followed up prospectively until the end of study. The interval of response evaluation is recommended to be every 2 to 3 months in the treatment period and the interval of follow-up is recommended to be every 2 to 3 months in the post-treatment period till the end of study in the prospective data collection period.
Interventions
DRUGDacomitinib
effectiveness and safety profile in patients with EGFR mutation-positive advanced NSCLC treated with dacomitinib (Vizimpro®) as the first-line treatment followed by 3rd generation EGFR-TKI in case the T790M resistance mutation was developed.
Sponsors
Peking Union Medical College
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A confirmed diagnosis of locally advanced or metastatic NSCLC. * The tumor harbored common EGFR mutations (Del19, L858R) at start of first-line treatment * Age ≥ 18 years * Had never received any EGFR TKI therapy. * Patients that treated with dacomitinib (Vizimpro®) as first-line treatment * Confirmation of the T790M variant after first line dacomitinib treatment and receive any 3rd generation EGFR-TKI as second-line treatment. * Asymptomatic CNS metastases allowed * At least one lesion that can be accurately measured at baseline according to the RECIST 1.1, and which is suitable for accurate repeated measurements. * Start second-line treatment with third generation EGFR TKI no later than 01 JAN2023（\>10 month before data cutoff date） * All eligible patients are required to sign an informed consent before initiating the study
Exclusion criteria
* Patients who received drug(s) other than 3rd generation EGFR-TKI as the second-line treatment and/or patients who received drug(s) other than Dacomitinib (Vizimpro®) as the first-line treatment * Received or currently receiving dacomitinib from any interventional clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| time to treatment failure | up to 4 years | To describe the time to treatment failure (TTF) of sequential dacomitinib and 3rd generation EGFR-TKI used in patients with EGFR mutation-positive NSCLC and T790M-aquired resistance in China. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| progression-free survival | up to 4 years | To describe the progression-free survival (PFS) of dacomitinib and 3rd generation EGFR-TKI used in patients with EGFR mutation-positive NSCLC with T790M-aquired resistance in China. |
| duration of treatment | up to 4 years | To describe the duration of treatment (DOT) of dacomitinib and 3rd generation EGFR-TKI used in patients with EGFR mutation-positive NSCLC with T790M-aquired resistance respectively in China. |
| overall survival | up to 5 years | To describe the overall survival (OS) of sequential dacomitinib and 3rd generation EGFR-TKI used in patients with EGFR mutation-positive NSCLC and T790M-aquired resistance in China. |
Countries
China
Contacts
Primary ContactPuyuan Xing, PhD
Outcome results
None listed